Genentech petrelintide sheds 10.7% weight in Phase II
03/05/2026 – 01:45 PM – Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-valueAt the…